Unit of Clinical Bioinformatics, Department of Pathology, Erasmus University Medical Centre, Rotterdam, Netherlands.
Tumor Immuno-Pathology Laboratory, Department of Pathology, Erasmus University Medical Centre, Rotterdam, Netherlands.
Front Immunol. 2021 Apr 27;12:649061. doi: 10.3389/fimmu.2021.649061. eCollection 2021.
The immune response affects tumor biological behavior and progression. The specific immune characteristics of pancreatic ductal adenocarcinoma (PDAC) can determine the metastatic abilities of cancerous cells and the survival of patients. Therefore, it is important to characterize the specific immune landscape in PDAC tissue samples, and the effect of various types of therapy on that immune composition. Previously, a set of marker genes was identified to assess the immune cell composition in different types of cancer tissue samples. However, gene expression and subtypes of immune cells may vary across different types of cancers. The aim of this study was to provide a method to identify immune cells specifically in PDAC tissue samples. The method is based on defining a specific set of marker genes expressed by various immune cells in PDAC samples. A total of 90 marker genes were selected and tested for immune cell type-specific definition in PDAC; including 43 previously used, and 47 newly selected marker genes. The immune cell-type specificity was checked mathematically by calculating the "pairwise similarity" for all candidate genes using the PDAC RNA-sequenced dataset available at The Cancer Genome Atlas. A set of 55 marker genes that identify 22 different immune cell types for PDAC was created. To validate the method and the set of marker genes, an independent mRNA expression dataset of 24 samples of PDAC patients who received various types of (neo)adjuvant treatments was used. The results showed that by applying our method we were able to identify PDAC specific marker genes to characterize immune cell infiltration in tissue samples. The method we described enabled identifying different subtypes of immune cells that were affected by various types of therapy in PDAC patients. In addition, our method can be easily adapted and applied to identify the specific immune landscape in various types of tissue samples.
免疫反应会影响肿瘤的生物学行为和进展。胰腺导管腺癌(PDAC)的特定免疫特征可以决定癌细胞的转移能力和患者的生存情况。因此,对 PDAC 组织样本中的特定免疫景观进行特征描述,并对各种类型的治疗对这种免疫成分的影响进行研究是很重要的。此前,已经确定了一组标记基因来评估不同类型癌症组织样本中的免疫细胞组成。然而,基因表达和免疫细胞亚型可能因不同类型的癌症而有所不同。本研究旨在提供一种方法来鉴定 PDAC 组织样本中的免疫细胞。该方法基于定义 PDAC 样本中各种免疫细胞表达的特定标记基因集。总共选择了 90 个标记基因,并对其在 PDAC 中的免疫细胞类型特异性定义进行了测试;包括 43 个先前使用的标记基因和 47 个新选择的标记基因。通过使用癌症基因组图谱中提供的 PDAC RNA 测序数据集,计算所有候选基因的“成对相似性”,从数学上检查免疫细胞类型特异性。创建了一组 55 个标记基因,用于鉴定 22 种不同的 PDAC 免疫细胞类型。为了验证该方法和标记基因集,使用了 24 名接受各种类型(新辅助)治疗的 PDAC 患者的独立 mRNA 表达数据集进行验证。结果表明,通过应用我们的方法,我们能够鉴定出 PDAC 特异性标记基因,以描绘组织样本中的免疫细胞浸润情况。我们描述的方法能够识别不同类型的免疫细胞,这些细胞受 PDAC 患者各种类型治疗的影响。此外,我们的方法可以很容易地适应和应用于鉴定各种类型组织样本中的特定免疫景观。